SEMA4C and cervical carcinoma: Similar to what reported above for breast cancer, experimental evidence indicated that Sema4C can promote EMT; moreover, it was found to sustain resistance to cisplatin-based chemotherapy in cervical cancer cells, while knocking-down its expression partly recovered drug sensitivity 56.